...
search icon
gmab-img

Genmab AS Share Price

GMAB
NSQ
$30
-$0.03
(-0.1%)
1D
Industry: Biotechnology Sector: Health Care

Genmab AS Analyst Forecast

Genmab AS Share Price Chart

Genmab AS Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$18.50B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
13.1135
Volume info-icon
This is the total number of shares traded during the most recent trading day.
3.04M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.80
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$17.23 L
$35.43 H
$30

About Genmab AS, Common Stock

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1042, GEN1059, GEN1055, and GEN1057 for solid tumors; GEN3014 for hematologic malignancies; GEN1160 for advanced solid and liquid tumors; and GEN1107 and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Novartis International AG, Medarex, Inc., ADC Therapeutics SA, Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Immatics, Novo Nordisk A/S, CureVac AG, Anthropic PBC, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark. more

Industry: BiotechnologySector: Health Care

Genmab AS Stock Returns

Time FrameGMABSectorS&P500
1-Week Return-1.96%1.51%-1.5%
1-Month Return-4.25%1.46%0.6%
3-Month Return-1.38%3.94%2.43%
6-Month Return28.1%16.03%6.01%
1-Year Return37.8%9.1%11.48%
3-Year Return-25%19.46%67.52%
5-Year Return-26.6%35.29%73.75%
10-Year Return178.97%137.42%254.46%

Genmab AS Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue10.11B8.42B14.51B16.47B21.53B[{"date":"2020-12-31","value":46.97,"profit":true},{"date":"2021-12-31","value":39.1,"profit":true},{"date":"2022-12-31","value":67.38,"profit":true},{"date":"2023-12-31","value":76.53,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue---226.00M985.00M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":22.94,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit10.11B8.42B14.51B16.25B20.54B[{"date":"2020-12-31","value":49.22,"profit":true},{"date":"2021-12-31","value":40.98,"profit":true},{"date":"2022-12-31","value":70.61,"profit":true},{"date":"2023-12-31","value":79.1,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin100.00%100.00%100.00%98.63%95.42%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":98.63,"profit":true},{"date":"2024-12-31","value":95.42,"profit":true}]
Operating Expenses3.80B5.46B8.24B10.93B13.84B[{"date":"2020-12-31","value":27.45,"profit":true},{"date":"2021-12-31","value":39.49,"profit":true},{"date":"2022-12-31","value":59.53,"profit":true},{"date":"2023-12-31","value":78.96,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income6.31B2.95B6.27B5.32B6.70B[{"date":"2020-12-31","value":94.18,"profit":true},{"date":"2021-12-31","value":44.05,"profit":true},{"date":"2022-12-31","value":93.5,"profit":true},{"date":"2023-12-31","value":79.38,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Total Non-Operating Income/Expense(235.00M)1.15B981.00M1.23B3.34B[{"date":"2020-12-31","value":-7.04,"profit":false},{"date":"2021-12-31","value":34.44,"profit":true},{"date":"2022-12-31","value":29.41,"profit":true},{"date":"2023-12-31","value":36.81,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income5.90B3.92B6.95B5.64B9.16B[{"date":"2020-12-31","value":64.43,"profit":true},{"date":"2021-12-31","value":42.75,"profit":true},{"date":"2022-12-31","value":75.79,"profit":true},{"date":"2023-12-31","value":61.51,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income Taxes1.15B961.00M1.49B1.28B1.32B[{"date":"2020-12-31","value":76.76,"profit":true},{"date":"2021-12-31","value":64.37,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":86.07,"profit":true},{"date":"2024-12-31","value":88.41,"profit":true}]
Income After Taxes4.76B2.96B5.45B4.35B7.84B[{"date":"2020-12-31","value":60.66,"profit":true},{"date":"2021-12-31","value":37.7,"profit":true},{"date":"2022-12-31","value":69.51,"profit":true},{"date":"2023-12-31","value":55.48,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income From Continuous Operations4.76B3.01B5.52B4.35B7.84B[{"date":"2020-12-31","value":60.66,"profit":true},{"date":"2021-12-31","value":38.35,"profit":true},{"date":"2022-12-31","value":70.4,"profit":true},{"date":"2023-12-31","value":55.48,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income4.76B2.96B5.45B4.35B7.84B[{"date":"2020-12-31","value":60.66,"profit":true},{"date":"2021-12-31","value":37.7,"profit":true},{"date":"2022-12-31","value":69.51,"profit":true},{"date":"2023-12-31","value":55.48,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
EPS (Diluted)8.150.731.160.951.74[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":8.96,"profit":true},{"date":"2022-12-31","value":14.23,"profit":true},{"date":"2023-12-31","value":11.66,"profit":true},{"date":"2024-12-31","value":21.35,"profit":true}]

Genmab AS Ratios

Genmab AS Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

GMAB
Cash Ratio 4.60
Current Ratio 6.03
Quick Ratio 6.01

Genmab AS Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

GMAB
ROA (LTM) 13.38%
ROE (LTM) 29.41%

Genmab AS Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

GMAB
Debt Ratio Lower is generally better. Negative is bad. 0.18
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.82

Genmab AS Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

GMAB
Trailing PE 13.11
Forward PE 11.03
P/S (TTM) 4.81
P/B 3.22
Price/FCF 35
EV/R 4.43
EV/Ebitda 9.00
PEG 0.58

FAQs

What is Genmab AS share price today?

Genmab AS (GMAB) share price today is $30

Can Indians buy Genmab AS shares?

Yes, Indians can buy shares of Genmab AS (GMAB) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GMAB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Genmab AS be purchased?

Yes, you can purchase fractional shares of Genmab AS (GMAB) via the Vested app. You can start investing in Genmab AS (GMAB) with a minimum investment of $1.

How to invest in Genmab AS shares from India?

You can invest in shares of Genmab AS (GMAB) via Vested in three simple steps:

  • Click on Sign Up or Invest in GMAB stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Genmab AS shares
What is Genmab AS 52-week high and low stock price?

The 52-week high price of Genmab AS (GMAB) is $35.43. The 52-week low price of Genmab AS (GMAB) is $17.23.

What is Genmab AS price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Genmab AS (GMAB) is 13.1135

What is Genmab AS price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Genmab AS (GMAB) is 3.22

What is Genmab AS dividend yield?

The dividend yield of Genmab AS (GMAB) is 0.00%

What is the Market Cap of Genmab AS?

The market capitalization of Genmab AS (GMAB) is $18.50B

What is Genmab AS's stock symbol?

The stock symbol (or ticker) of Genmab AS is GMAB

How Can Investors Use Genmab AS Share Price Data for Long-Term Investment Decisions?

Consider the share price of Genmab AS as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Genmab AS has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Genmab AS shares for Indian investors?

When investing in Genmab AS shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Genmab AS stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Genmab AS share price with other stocks in the same sector?

Rather than merely checking the share price of Genmab AS and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Genmab AS stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top